Problem of using hemoglobin A1C measurement in endemic area of hemoglobinopathy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 18632040.
- Also identified by DOI 10.1016/j.pcd.2007.07.004.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Diabetes mellitus (DM) is a frequent disorder affecting individuals of all ages. Glycohemoglobin (GHb) has a key role in the assessment of glycemic control in diabetic patients. Generally, GHb is measured as hemoglobin (Hb) A1C and is the result of an irreversible non-enzymatic glycation of the beta chain of hemoglobin A. HbA1C is used routinely to assess long term glycemic control in patients with DM. A variety of patient- and laboratory-related factors can adversely affect the measurement of HbA1C in patients harboring Hb variants or derivatives. In this article, problem of using hemoglobin A1C measurement in endemic area of hemoglobinopathy is addressed.
Medical subject headings
- Diabetes Mellitus
- Glycated Hemoglobin
- Hemoglobinopathies